盐酸四环素药敏可预测多西环素敏感性,但对米诺环素和替加环素不可靠
该研究基于SENTRY全球监测数据,分析69 259株临床分离菌,评估盐酸四环素药敏预测多西环素、米诺环素和替加环素敏感性的可靠性。结果显示盐酸四环素可预测部分菌种对多西环素的敏感性,但不能可靠预测米诺环素和替加环素(除金黄色葡萄球菌外),提示不应普遍用其替代四环素衍生物的药敏试验。
要点
- 盐酸四环素可预测肺炎链球菌等5类菌对多西环素的敏感性(CA>90%,VME≤1.5%)。
- 除金黄色葡萄球菌外,盐酸四环素不能可靠预测米诺环素和替加环素敏感性。
- 四环素衍生物的药敏试验对优化临床用药仍至关重要。
核心结论
- 盐酸四环素不应普遍用于预测四环素衍生物的敏感性。
- 对米诺环素和替加环素的预测尤其不可靠。
- 四环素衍生物体外药敏试验仍是优化临床用药的关键。
研究设计与样本
- 基于SENTRY全球抗菌药物监测项目数据的回顾性分析。
- 纳入2017–2019年或2013–2014年美国及欧洲123家医疗中心的69 259株临床分离菌。
- 采用肉汤微量稀释法进行药敏试验,并应用CLSI、EUCAST或FDA折点。
主要发现
- 盐酸四环素可预测Klebsiella spp.、Enterobacter spp.、金黄色葡萄球菌、β-溶血链球菌和肺炎链球菌对多西环素的敏感性(CA>90%,VME≤1.5%)。
- 除金黄色葡萄球菌外,盐酸四环素不能可靠预测任何受试菌对米诺环素和替加环素的敏感性。
- 对金黄色葡萄球菌,盐酸四环素预测米诺环素和替加环素敏感性的CA分别为94.4%和93.8%,VME均为0%。
关键数值与推荐
- 可靠性替代标准:VME≤1.5%且CA≥90%。
- 多西环素预测可靠菌种:Klebsiella spp.、Enterobacter spp.、金黄色葡萄球菌、β-溶血链球菌、肺炎链球菌。
- 米诺环素和替加环素预测可靠菌种仅金黄色葡萄球菌(CA=94.4%和93.8%,VME=0%)。
临床怎么用
- 对Klebsiella spp.、Enterobacter spp.、金黄色葡萄球菌、β-溶血链球菌和肺炎链球菌,可用盐酸四环素药敏预测多西环素敏感性。
- 对米诺环素和替加环素,除金黄色葡萄球菌外,应直接进行药敏试验,不应以盐酸四环素替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antimicrobial susceptibility testing of multiple antimicrobial agents within the same class remains challenging for clinical microbiology laboratories. The evidence behind the use of tetracycline hydrochloride (HCl) susceptibility as a predictor for minocycline, doxycycline, and tigecycline susceptibility was evaluated in clinical Gram-negative and Gram-positive bacterial isolates, analysing the SENTRY Antimicrobial Surveillance Programme, an extensive and representative global antimicrobial resistance dataset. METHODS: Tetracycline hydrochloride to predict susceptibility to doxycycline, minocycline, and tigecycline was studied in 69 259 bacterial isolates of Escherichia spp., Klebsiella spp., Enterobacter spp., Haemophilus influenzae, Acinetobacter spp., Staphylococcus spp., Streptococcus spp., and Enterococcus spp. collected from 123 medical centres in the United States and Europe between 2017 and 2019 or between 2013 and 2014. Antimicrobial susceptibility testing was performed using the broth microdilution method. Clinical and Laboratory Standards Institute breakpoints were applied when available; in their absence, the European Committee on Antimicrobial Susceptibility Testing and U.S. Food and Drug Administration breakpoints were used. To be considered a reliable surrogate for susceptibility, the very major error (VME) rate comparing tetracycline HCl with the tetracycline derivatives should be ≤ 1.5%, and the category agreement (CA) should be ≥ 90%. RESULTS: Tetracycline HCl is a surrogate for doxycycline susceptibility for Klebsiella spp., Enterobacter spp., Staphylococcus aureus, β-hemolytic Streptococcus, and Streptococcus pneumoniae (high CA >90% and low VME ≤1.5%). Tetracycline HCl could not reliably predict susceptibility to minocycline and tigecycline in any of the tested bacteria except S. aureus (CA = 94.4% and 93.8%, respectively, and VME = 0% for both). CONCLUSIONS: Tetracycline HCl should not be universally used to predict susceptibility to tetracycline derivatives, especially to minocycline and tigecycline. Tetracycline derivatives in vitro susceptibility testing remains crucial to optimizing their clinical use.
引用
- Sfeir MM. Tetracycline hydrochloride susceptibility for prediction of antimicrobial susceptibility to doxycycline, minocycline, and tigecycline against Gram-negative and Gram-positive bacteria. Clin Microbiol Infect. 2025. PMID: 41429685. doi:10.1016/j.cmi.2025.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。